Sanofi: revised financial statements (excluding Opella)
(CercleFinance.com) - Sanofi has revised its financial statements (Sanofi excluding Opella).
This follows the press release of 21 October 2024 and the proposed sale of a 50% majority stake in Opella (consumer healthcare division) to CD&R. Sanofi's revised financial statements reflecting the new scope, excluding Opella, are now available.
Adjustments to the financial statements reclassify Opella's activities as discontinued operations.
Sanofi would become a biopharmaceutical company focused on science and committed to delivering innovative medicines and vaccines to patients, it says.
The revised financial data, which has been reviewed by Sanofi's auditors, includes details of Sanofi's net sales, business net income and published IFRS accounts, excluding Opella.
From Q4 2024 and until the closing of the transaction, Opella's income, net of tax, will be included in "Net income from discontinued operations" in Sanofi's income statement. This classification as a discontinued operation also applies to the previous quarters of 2024, and for comparative purposes to all quarters of 2023.
Sanofi's Q4 2024 results are due on 30 January 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This follows the press release of 21 October 2024 and the proposed sale of a 50% majority stake in Opella (consumer healthcare division) to CD&R. Sanofi's revised financial statements reflecting the new scope, excluding Opella, are now available.
Adjustments to the financial statements reclassify Opella's activities as discontinued operations.
Sanofi would become a biopharmaceutical company focused on science and committed to delivering innovative medicines and vaccines to patients, it says.
The revised financial data, which has been reviewed by Sanofi's auditors, includes details of Sanofi's net sales, business net income and published IFRS accounts, excluding Opella.
From Q4 2024 and until the closing of the transaction, Opella's income, net of tax, will be included in "Net income from discontinued operations" in Sanofi's income statement. This classification as a discontinued operation also applies to the previous quarters of 2024, and for comparative purposes to all quarters of 2023.
Sanofi's Q4 2024 results are due on 30 January 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.